Li Meng serves as Chief Operating Officer, Secretary, Director of the Company. Ms. Li has over 15 years of executive experience in international marketing, branding, communications, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenith Media (a Publicis Group company) from 2000 to 2006 as Senior Manager. Ms. Li received a Bachelor of Arts in International Economic Law from Dalian Maritime University in China.
As the Chief Operating Officer, Secretary oraz Director of Avalon GloboCare Corp, the total compensation of Li Meng at Avalon GloboCare Corp is $768,722. There are 3 executives at Avalon GloboCare Corp getting paid more, with Lu Wenzhao having the highest compensation of $4,047,220.
Li Meng is 42, she's been the Chief Operating Officer, Secretary oraz Director of Avalon GloboCare Corp since 2017. There are 12 older and no younger executives at Avalon GloboCare Corp. The oldest executive at Avalon GloboCare Corp is Wilbert Tauzin, 76, who is the Director.
Meng's mailing address filed with the SEC is C/O AVALON GLOBOCARE CORP.,, 4400 ROUTE 9, SUITE 3100, FREEHOLD,, NJ, 07728.
Over the last 8 years, insiders at Avalon GloboCare Corp have traded over $2,500,000 worth of Avalon GloboCare Corp stock and bought 898,876 units worth $1,418,962 . The most active insiders traders include Wenzhao Lu, Luisa Ingargiola oraz Steven Andrew Sanders. On average, Avalon GloboCare Corp executives and independent directors trade stock every 157 days with the average trade being worth of $446,629. The most recent stock trade was executed by Wenzhao Lu on 1 April 2020, trading 645,161 units of AVCO stock currently worth $1,000,000.
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Avalon GloboCare Corp executives and other stock owners filed with the SEC include: